Stereotactic Ablative Radiotherapy (SABR) is a type of cancer treatment that uses precise, high-dose radiation to target and destroy cancer cells. This study is looking at SABR's safety and effectiveness in patients with a type of lung cancer called non-small cell lung cancer (NSCLC) that has spread to a few other areas, known as oligo-metastatic (oligo-M). Oligo-M means having 1-5 spots where the cancer has spread.

There are two types: synchronous oligo-M, which happens within 4-6 months of the first cancer diagnosis, and metachronous oligo-M, which occurs after initial treatment of the main tumor. The study involves combining SABR with targeted therapies or immunotherapy to see if this approach helps in controlling the disease and improving survival without adding severe side effects.

• Patients will need to visit the study location for SABR treatments.
• The study combines SABR with other therapies to manage lung cancer spread.
• Participants should not be pregnant due to risks from radiation therapy.